Scientific American reports: "Countless scientific studies have shown that medical cannabis offers palliative care benefits, including appetite stimulation, pain relief and more. But early research indicates that cannabinoids can do so much more. Data is showing that medical marijuana has antitumor effects and may one day be used as a cancer treatment, not just as a drug to ease symptoms of the disease." Full article.
A renaissance is coming to New Jersey’s long embattled medical marijuana program.
Democratic Gov. Phil Murphy announced a long list of reforms this morning, including lowering fees for patients and caregivers, adding five approved medical conditions and proposing legislation to increase monthly product limit for patients.
Patients receiving hospice care would be eligible for an unlimited supply of cannabis. Effective immediately, patients suffering from anxiety, migraines, Tourette’s syndrome, chronic pain related to musculoskeletal disorders, and chronic visceral pain will be eligible for the medical cannabis program.
Murphy added that he would like to eventually see opioid addiction added to the growing list of approved conditions. He called cannabis “an offensive weapon” to the growing crisis.
Medical cannabis therapy can significantly reduce chronic pain in patients age 65 and older without adverse effects, according to researchers at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical Center.
The new study found that cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson’s disease, post-traumatic stress disorder, ulcerative colitis, Crohn’s disease, multiple sclerosis, and other medical issues.
“While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,” says Victor Novack, a Professor of Medicinein the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.
“After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.” Read full article here and review research here.
Seniors are among one of the largest existing and growing demographics of medical cannabis users, evidenced by international trends as well as supported by the data collected from the Strainprint app, a mobile application that helps medical cannabis users track their intake and learn which strains and dosages work best for them. Strainprint also provides doctors and clinics with observational data to improve industry treatment knowledge. Based on their current data, here are the top five conditions for which people aged 65 and over are using medical cannabis. Full article.
The San Francisco Chronicle reports that National Basketball Players Association (NPBA) Executive Director Michele Roberts has voiced her support for lifting the league’s ban on marijuana in the near future.
“My own view is that there are substantial signs that support its efficacy and the value that it has for us, especially pain management,” Roberts told SB Nation.” We’re in talks with the league to see where we can go with it.” Full article.
Dr. Blake Pearson partners with Trillium Villa on a new, trailblazing collaboration to determine whether medicinal marijuana can improve quality of life for residents of Sarnia's long-term care community who are living with conditions such as chronic pain, movement disorders and anxiety. Read here.
Dr. Blake Pearson says, “In my clinic daily, I see the benefits of THC and CBD, and in a continuing care facility we see patients suffering from chronic pain, sleep disorders, and dementia-related anxiety. I think it’s a natural fit to try it out and hopefully reduce some of the polypharmacy going on in those types of settings." Full article.
The Canadian Pain Society has advanced cannabinoid therapy from a fourth-line (2007) to the third-line (2014) recommendation, citing the following evidence:
- Since 2006, seven high quality studies investigated cannabinoid therapy in neuropathic pain, and all but one of these studies had positive results.
- Mucosal spray of 50/50 mixture of THC/CBD provided significant pain relief for patients with multiple sclerosis.
- One trial found that nabilone was effective for pain relief in patients with painful diabetic neuropathy, with improved sleep and overall quality of life.
- There is increasing evidence of the benefits of cannabinoid therapy in managing neuropathic pain: overall NNT of 3.4.